Drug
Odm 212
Odm 212: highest development phase Phase 1/2, developed by Orion Corporation. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Orion Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| ODM-212 NCT07563738 | Phase 1/2 | Mesothelioma |
| ODM-212 NCT06725758 | Phase 1/2 | Solid Tumours |
Latest
Follow Odm 212 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.